We recognize that many American College of Cardiology (ACC) members are involved in supporting efforts to contain and treat COVID-19. Thank you for all you do to bring health and safety to your patients every day.

ACC’s scientific exchanges are critical; thus, we remain committed to supporting ACC regardless of its annual congress format. We look forward to seeing you online this year and in person in 2021.

Follow Along on twitter


Session 405: Joint American College of Cardiology/New England Journal of Medicine Late-breaking Clinical Trials II

Transcatheter Aortic Valve Replacement in Patients with Severe Bicuspid Aortic Valve Stenosis at Low Predicted Risk of Mortality

March 29 | 8:15 a.m. CT
Presented by: Basel Ramlawi, M.D.

Session 406: Late-breaking Clinical Trials III

Catheter-based Renal Denervation in the Absence of Antihypertensive Medications: Primary Results from the SPYRAL HTN-OFF MED Pivotal Trial

March 29 | 11:30 a.m. CT
Presented by: Prof. Michael Böhm


Optimizing Outcomes in Transcatheter Aortic Valve Implantation

Transcatheter Aortic Valve Implant Depth Measurements Differ by Aortography versus Computed Tomography

March 28
Presented by: Amit N. Vora, M.D.

Optimizing Outcomes in Transcatheter Aortic Valve Implantation

5-year Health Status Outcomes after Self-expanding Transcatheter or Surgical Aortic Valve Replacement in High-risk Patients with Severe Aortic Stenosis

March 28
Presented by: Suzanne Arnold, M.D.

Arrhythmias and Clinical EP: Devices 3

Use of Clinic Management Software to Evaluate the Effectiveness of Care Pathways for Cardiac Device Patients with Atrial Fibrillation

March 28
Presented by: Melissa Allen, CCT, LMR, CCDS

Highlighted Original Research: Interventional Cardiology and the Year in Review

One-month Dual Antiplatelet Therapy in High Bleeding Risk Patients: Primary Results from the Onyx ONE Clear Study

March 28
Presented by: Ajay Kirtane M.D.

Highlighted Original Research: Interventional Cardiology and the Year in Review

Leaflet Thickening or Immobility in Transcatheter or Surgical Aortic Valves: Results from the EVOLUT Low Risk LTI Substudy

March 28
Presented by: Jeffrey Popma, M.D.

Explore the data

Onyx One Clear Study

Advancing 1-month DAPT evidence in highly complex high bleeding risk patients, including subjects from the U.S. and Japan.*

Learn About The Study
Image of Resolute Onyx DES on light blue gradient background

*Resolute Onyx™ DES is not currently indicated for high bleeding risk patients on 1-month DAPT in the United States.

Above and Beyond

Learn more about EvolutTM TAVR hemodynamics — and why EOAs, gradients, and patient-prosthesis mismatch all matter in TAVR.

Review the Data
Top down image of Evolut TAVR Platform valve enlarged to show superior EOAs and Hemodynamics


I’m a healthcare professional:

CAUTION: Investigational device. Limited by federal (U.S.) law to investigational use.


SCAI 2020 Virtual Attendance
May 13–16

TVT 2020 Chicago, Illinois
June 17–20 

CVI 2020 Denver, Colorado
July 8–11